Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.
Int Neurourol J. 2014 Mar;18(1):23-30. doi: 10.5213/inj.2014.18.1.23. Epub 2014 Mar 31.
To determine the baseline clinical characteristics associated with dose escalation of solifenacin in patients with overactive bladder (OAB).
We analyzed the data of patients with OAB (micturition frequency ≥8/day and urgency ≥1/day) who were treated with solifenacin and followed up for 24 weeks. According to our department protocol, all the patients kept voiding diaries, and OAB symptom scores (OABSS) were monitored at baseline and after 4, 12, and 24 weeks of solifenacin treatment.
In total, 68 patients (mean age, 60.8±10.0 years) were recruited. The dose escalation rate by the end of the study was 41.2%, from 23.5% at 4 weeks and 17.6% at 12 weeks. At baseline, the dose escalator group had significantly more OAB wet patients (53.6% vs. 20.0%) and higher total OABSS (10.2±2.4 vs. 7.9±3.5, P=0.032) than the nonescalator group. OAB wet (odds ratio [OR], 4.615; 95% confidence interval [CI], 1.578-13.499; P<0.05) and total OABSS (OR, 1.398; 95% CI, 1.046-1.869; P<0.05) were found to be independently associated with dose escalation.
Patients who have urgency urinary incontinence and high total OABSS have a tendency for dose escalation of solifenacin.
确定与膀胱过度活动症（OAB）患者索利那新剂量递增相关的基线临床特征。
我们分析了接受索利那新治疗并随访 24 周的 OAB 患者（排尿频率≥8 次/天和尿急≥1 次/天）的数据。根据我们科室的方案，所有患者都保留排尿日记，并在基线以及索利那新治疗 4、12 和 24 周后监测 OAB 症状评分（OABSS）。
共纳入 68 例患者（平均年龄 60.8±10.0 岁）。研究结束时，剂量递增率为 41.2%，第 4 周和第 12 周分别为 23.5%和 17.6%。基线时，剂量递增组 OAB 湿患者（53.6%比 20.0%）和总 OABSS（10.2±2.4 比 7.9±3.5，P=0.032）显著高于非递增组。OAB 湿（比值比 [OR]，4.615；95%置信区间 [CI]，1.578-13.499；P<0.05）和总 OABSS（OR，1.398；95% CI，1.046-1.869；P<0.05）被发现与剂量递增独立相关。
有急迫性尿失禁和高总 OABSS 的患者有索利那新剂量递增的趋势。
